QQQ $ 589.91 $ -21.69 (-3.55 %)
DIA $ 459.99 $ -6.69 (-1.43 %)
SPY $ 656.46 $ -16.44 (-2.45 %)
TLT $ 89.18 $ 0.19 (0.21 %)
GLD $ 375.36 $ 0.18 (0.05 %)
$ 0.049
-- x --
-- x --
-- - --
$ 0.04 - $ 0.19
491,462
na
1.65M
$ 2.09
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-19-2025 09-30-2025 10-Q
2 08-19-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 04-15-2025 12-31-2024 10-K
5 11-26-2024 09-30-2024 10-Q
6 08-19-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 04-16-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-07-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-31-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 03-31-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 03-29-2021 12-31-2020 10-K
21 11-16-2020 09-30-2020 10-Q
22 08-14-2020 06-30-2020 10-Q
23 05-13-2020 03-31-2020 10-Q
24 04-03-2020 12-31-2019 10-K
25 11-14-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 05-20-2019 03-31-2019 10-Q
28 04-16-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-21-2018 03-31-2018 10-Q
32 04-17-2018 12-31-2017 10-K
33 11-14-2017 09-30-2017 10-Q
34 08-21-2017 06-30-2017 10-Q
35 05-15-2017 03-31-2017 10-Q
36 03-31-2017 12-31-2016 10-K
37 11-14-2016 09-30-2016 10-Q
38 08-10-2016 06-30-2016 10-Q
39 05-12-2016 03-31-2016 10-Q
40 03-29-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 windtree-therapeutics-q3-eps-108-up-from-21138-yoy

Windtree Therapeutics (OTC:WINT) reported quarterly losses of $(1.08) per share. This is a 99.49 percent increase over losses o...

 windtree-therapeutics-terminates-seismic-c-clinical-study-at-20-enrollments-termination-due-to-limited-resources-not-safety-concerns

-SEC Filing

 windtree-therapeutics-performs-planned-interim-analysis-of-seismic-c-phase-2-study-data-evaluating-istaroxime-in-scai-stage-c-cardiogenic-shock

Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and...

 why-are-public-companies-amassing-eth-xrp-sol-bnb-instead-of-just-bitcoin

Publicly traded companies are increasingly integrating cryptocurrencies other than Bitcoin (CRYPTO: BTC), into their treasuries...

 windtree-enters-into-common-stock-purchase-agreement-for-up-to-500m-to-establish-equity-line-of-credit-and-bolster-bnb-cryptocurrency-treasury-strategy

Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury StrategyNinety Nine Percent of the pro...

 windtree-therapeutics-announces-up-to-520m-in-new-funding-for-its-cryptocurrency-treasury-strategy

Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury StrategyNinety Nine Percent of the pro...

 windtree-therapeutics-partners-with-kraken-to-provide-custody-trading-and-over-the-counter-services-for-windtrees-bnb-crypto-treasury-strategy

Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT) is pleased to announce a strategic p...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION